Diagnoptics News

What's new?

Read all news items about the AGE Reader and Diagnoptics.

Diabetes Risk Test Prototype

Groningen, the Netherlands – November 5th 2018,

In the Netherlands, as in most other countries, the impact of diabetes in terms of health and cost is very large and still increasing.
In addition, forty percent of diabetes patients have not yet been diagnosed. It is precisely through early detection of people who are at an increased risk of developing diabetes that there is much health gain to be achieved, both for public health and for the individual.

This can prevent (chronic) complications, such as cardiovascular disease. However, currently an accessible and easy way to pre-medically screen people does not exist. That is why Diagnoptics in cooperation with Dutch pharmacy ‘de Vriendschap’ is developing a diabetes risk test prototype based on the non-invasive AGE measurement.

By performing this test at the pharmacy clients can easily check whether they are at an increased risk of developing diabetes and receive further advice. This project is made possible through a contribution of the European Union from the Europees Fonds voor Regionale Ontwikkeling (EFRO).

Share this link on:

Latest news items

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
Age Reader MU
The 'AGE Reader mu' is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors. Read more »
Newsletter subscription

If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.